The Monark trial: Where now for boosted protease inhibitor monotherapy?

AIDS

Volumn 22, Issue 6, 2008, Pages 777-779

  Hill, Andrew ^a   Hirschel, Bernard ^b   Katlama, Christine ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Clinical trials; Efficacy; hiv rna; Monotherapy; Nucleoside analogues; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPOATROPHY; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG HALF LIFE; DRUG TREATMENT FAILURE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; THERAPY EFFECT; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; TREATMENT OUTCOME;

EID: 41349116602     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f3f17f     Document Type: Note

References (11)

1. Hill A, DeMasi R. Discordant conclusions from HIV efficacy trials - an evaluation of efficacy endpoints. Antivir Ther 2005; 10:367-374.
2. Miró O, López S, Cardellach F, Casademont J. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther 2005; 10 (Suppl 2): M73-M81.
3. Delfraissy J, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard P, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients: the Monark Trial. AIDS 2008; 22:385-393.
4. King M, Rode R, Cohen-Codar I, Calvez V, Marcelin A, Hanna G, Kempf D. Predictive genotypic algorithm for virologic response to lopinavi-ritonavir in protease inhibitor experienced patients. Antimicrob Agents Chemother 2007; 51:3067-3074.
5. Johnson V, Brun-Venizet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
6. Cameron D, da Silva B, Arribas J, Myers R, Bellos N, Gilmore N, et al. A two-year randomised controlled clinical trial in antiretroviral-naive patients using lopinavir/ritonavir monotherapy after initial induction treatment compared to an efavirenz 3-drug regimen: 96 week results (Study M03-613). In: XVIth International AIDS Conference. Toronto, Canada; 13-18 August 2006. Abstract THLB0201.
7. Arribas J, Pulido F, Delgado R, Gonzalez-Garcia J, Perez-Elias M, Arranz A, et al. Lopinavir-ritonavir monotherapy vs lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. Ninety-six week results of a randomised controlled, open-lebel, clinical trial (OK-04 Study). In: 11th European AIDS Conference (EACS). Madrid, Spain; 24-27 October 2007. Abstract PS3.1.
8. Nunes E, Oliveira M, Almeida M, Pilotto J, Ribeiro J, Faulhaber J, et al. 96-Week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/ml on HAART - the KalMo Study. In: 11th European AIDS Conference (EACS). Madrid, Spain; 24-27 October 2007. Abstract P7.5/04.
9. Phillips AN, Walker S. Drug switching and virologic based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18:365-370.
10. Klein C, Chiu Y, Awni W, Zhu T, Heuser R, Doan TMD. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410.
11. Darunavir prescribing information 2006. Available at: www. aidsinfo.nih.gov/drugs. Accessed October 2007.